Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patien...
Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
About this item
Full title
Author / Creator
Sabado, Rachel L , Pavlick, Anna , Gnjatic, Sacha , Cruz, Crystal , Vengco, Isabelita , Hasan, Farah , Darvishian, Farbod , Chiriboga, Luis , Holman, Rose Marie , Escalon, Juliet , Muren, Caroline , Escano, Crystal , Yepes, Ethel , Sharpe, Dunbar , Adams, Sylvia , Ott, Patrick , Jungbluth, Achim , Pan, Linda , Venhaus, Ralph and Bhardwaj, Nina
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
PurposeThe TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine adjuvants. In this study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when...
Alternative Titles
Full title
Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
Authors, Artists and Contributors
Author / Creator
Pavlick, Anna
Gnjatic, Sacha
Cruz, Crystal
Vengco, Isabelita
Hasan, Farah
Darvishian, Farbod
Chiriboga, Luis
Holman, Rose Marie
Escalon, Juliet
Muren, Caroline
Escano, Crystal
Yepes, Ethel
Sharpe, Dunbar
Adams, Sylvia
Ott, Patrick
Jungbluth, Achim
Pan, Linda
Venhaus, Ralph
Bhardwaj, Nina
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3991251
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3991251
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1186/2051-1426-1-S1-P272
